Discussion | Pseudotumor cerebri is characterized by symptoms of increased intracranial pressure: headache, visual disturbances (blurry vision, diplopia), nausea and vomiting, and stiff neck.
1 It is commonly idiopathic, primarily affecting women of childbearing age who are overweight. Less frequently, it can occur in association with other disease conditions (usually endocrinologic abnormalities such as polycystic ovarian syndrome).
2
Despite many anecdotal reports of drug-associated PTC, there are 4 primary drug classes that are considered by experts to have a true association with PTC 1,3 : (1) tetracyclines, including doxycycline and minocycline; (2) oral retinoids; (3) recombinant growth hormone; and (4) corticosteroids (following withdrawal). Cross-reactivity between these drug classes in patients with drug-associated PTC has not been reported. Symptoms usually regress completely after discontinuation of the drug therapy.
1,4
The pathophysiological mechanisms of drug-associated PTC are not fully understood. It has been postulated that tetracyclines may reduce cerebrospinal fluid outflow at the arachnoid villi, while oral retinoids (through excess retinols and retinol-binding protein) may be directly toxic to arachnoid villi function. 5, 6 We report safe use of isotretinoin in 3 patients with histories of drug-associated PTC. When acne warrants isotretinoin treatment, a patient history of PTC should not preclude its use if careful surveillance for PTC recurrence can be conducted. Baseline evaluation by ophthalmology and/or neurology services should be considered. 
Melanoma Gene Expression Markers for Surveillance of Epidermolysis Bullosa Nevi Malignant Transformation
The evaluation of malignant changes in epidermolysis bullosa (EB) nevi remains a challenge for clinicians; herein, we introduce the idea of employing melanoma gene expression markers to aid in thorough histopathologic examination of suspicious EB nevi lesions.
Report of a Case | A young girl with epidermolysis bullosa simplex (EBS) initially came under our care at age 4 years. Two years after her first presentation, she developed an irregular brown-black patch on her left lateral ankle. The lesion was a 3.6 × 3 cm triangular hyperpigmented, asymptomatic patch consisting of confluent mottled black and brown macules and several satellite lesions consistent with an EB nevus.
The patient returned at age 9 years and the parents noted slow but progressive growth of the hyperpigmented patch on her left ankle. On examination, several brown macules coalescing into a 5.5 × 5-cm patch with surrounding satellite lesions was seen on her lateral ankle ( Figure 1A) . Biopsy was performed of a representative area, showing a compound nevus with large nested melanocytes and bridging at the dermalepidermal junction consistent with an atypical compound nevus ( Figure 1B) .
The patient was seen for follow-up every 6 months. The atypical nevus remained unchanged until age 12 years, when 2 discrete areas of regression were noted (Figure 2A) . On dermoscopy, discontiguous and irregular homogenous blue, brown, and gray areas with gray-brown structureless areas and a negative pigment network were observed, suggestive of malignant transformation. No induration was palpated except at the previous biopsy site.
Repeated biopsy of the areas of clinical regression showed atypical nevus with areas of dermal fibrosis ( Figure 2B ). Gene expression testing for 23 melanoma genes was performed yielding a melanoma gene expression test (Myriad myPath; Myriad Genetics) score of −7.1, where scores from −16.7 to −2.1 are consistent with a benign nevus.
The score, in combination with the histopathologic findings, indicated that the changes seen on the clinical examination were benign. Therefore, we managed the lesion with conservative observation.
Discussion | Epidermolysis bullosa nevi in patients with EBS have been largely thought to be of low malignant potential despite their alarming mimicry of melanoma. However, with the recent report of a malignant transformation of a With the use of melanoma gene expression markers, smaller biopsy samples can differentiate malignant transformations from benign lesions with high sensitivity and specificity.
5 Employing such gene expression markers can be especially helpful in cases of atypia seen on histopathologic examination because the markers can aid in distinguishing pseudomelanomatous changes from true malignant transformations. With the use of melanoma markers in combination with traditional histopathologic analysis, clinicians may also identify subtler changes of a malignant transformation earlier, ultimately leading to decreased morbidity and mortality of patients.
